476 related articles for article (PubMed ID: 32234712)
1. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
[TBL] [Abstract][Full Text] [Related]
2. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
3. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
[TBL] [Abstract][Full Text] [Related]
4. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
[TBL] [Abstract][Full Text] [Related]
5. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
6. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B
Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302
[TBL] [Abstract][Full Text] [Related]
7. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study.
Bech AB; Clausen T; Waal H; Šaltytė Benth J; Skeie I
BMC Health Serv Res; 2019 Jul; 19(1):440. PubMed ID: 31266495
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
9. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
[TBL] [Abstract][Full Text] [Related]
10. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
11. Methadone maintenance treatment and mortality in people with criminal convictions: A population-based retrospective cohort study from Canada.
Russolillo A; Moniruzzaman A; Somers JM
PLoS Med; 2018 Jul; 15(7):e1002625. PubMed ID: 30063699
[TBL] [Abstract][Full Text] [Related]
12. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
13. Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis.
Bahji A; Cheng B; Gray S; Stuart H
Acta Psychiatr Scand; 2019 Oct; 140(4):313-339. PubMed ID: 31419306
[TBL] [Abstract][Full Text] [Related]
14. Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada.
Kurz M; Min JE; Dale LM; Nosyk B
J Subst Abuse Treat; 2022 Feb; 133():108647. PubMed ID: 34740484
[TBL] [Abstract][Full Text] [Related]
15. Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
Homayra F; Hongdilokkul N; Piske M; Pearce LA; Zhou H; Min JE; Krebs E; Nosyk B
Drug Alcohol Depend; 2020 Feb; 207():107798. PubMed ID: 31927163
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
Piske M; Thomson T; Krebs E; Hongdilokkul N; Bruneau J; Greenland S; Gustafson P; Karim ME; McCandless LC; Maclure M; Platt RW; Siebert U; Socías ME; Tsui JI; Wood E; Nosyk B
BMJ Open; 2020 Sep; 10(9):e036102. PubMed ID: 32912944
[TBL] [Abstract][Full Text] [Related]
17. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
18. Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada.
Guerra-Alejos BC; Yan Y; Kurz M; Mudalige N; Min JE; Homayra F; Nosyk B
Addiction; 2024 Apr; ():. PubMed ID: 38584294
[TBL] [Abstract][Full Text] [Related]
19. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
20. Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study.
Slaunwhite A; Min JE; Palis H; Urbanoski K; Pauly B; Barker B; Crabtree A; Bach P; Krebs E; Dale L; Meilleur L; Nosyk B
BMJ; 2024 Jan; 384():e076336. PubMed ID: 38199614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
